A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10386 in Participants With Advanced Solid Tumors
Latest Information Update: 29 Jun 2023
At a glance
- Drugs HS-10386 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 29 Jun 2023 New trial record